Page last updated: 2024-09-03

amarogentin and Alloxan Diabetes

amarogentin has been researched along with Alloxan Diabetes in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chandel, S; Dixit, M; Gromiha, MM; Manoj, N; Mehta, N; Potunuru, UR; Priya, KV; Raman, T; Ramar, M; Varsha, MKNS	1
Chao, PC; Cheng, JT; Ku, PM; Lee, KS; Niu, CS; Niu, HS	1

Other Studies

2 other study(ies) available for amarogentin and Alloxan Diabetes

Article	Year
Amarogentin, a secoiridoid glycoside, activates AMP- activated protein kinase (AMPK) to exert beneficial vasculo-metabolic effects. Biochimica et biophysica acta. General subjects, 2019, Volume: 1863, Issue:8 Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Calorimetry; Diabetes Mellitus, Experimental; Endothelium, Vascular; Enzyme Activation; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Iridoids; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Rats; Signal Transduction; Tumor Necrosis Factor-alpha	2019
Amarogentin ameliorates diabetic disorders in animal models. Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:11 Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dose-Response Relationship, Drug; Fructose; Glucose Tolerance Test; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Iridoids; Liver; Male; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); Rats, Wistar; Streptozocin	2016

Article

Year

Amarogentin, a secoiridoid glycoside, activates AMP- activated protein kinase (AMPK) to exert beneficial vasculo-metabolic effects.

Biochimica et biophysica acta. General subjects, 2019, Volume: 1863, Issue:8

Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Calorimetry; Diabetes Mellitus, Experimental; Endothelium, Vascular; Enzyme Activation; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Iridoids; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Rats; Signal Transduction; Tumor Necrosis Factor-alpha

2019

Amarogentin ameliorates diabetic disorders in animal models.

Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:11

Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dose-Response Relationship, Drug; Fructose; Glucose Tolerance Test; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Iridoids; Liver; Male; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); Rats, Wistar; Streptozocin

2016